Akebia Therapeutics (AKBA) Capital Expenditures (QoQ) (2014 - 2026)
Akebia Therapeutics (AKBA) Capital Expenditures (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.66% |
| Mar 31, 2026 | -68.80% |
| Dec 31, 2025 | 3,018.18% |
| Sep 30, 2025 | -38.89% |
| Jun 30, 2025 | 600.00% |
| Mar 31, 2025 | 102.76% |
| Dec 31, 2024 | -235.20% |
| Sep 30, 2024 | 145.35% |
| Jun 30, 2024 | -273.74% |
| Mar 31, 2024 | 107.50% |
| Dec 31, 2023 | -200.00% |
| Sep 30, 2023 | 390.72% |
| Jun 30, 2023 | -200.00% |
| Sep 30, 2022 | 267.48% |
| Jun 30, 2022 | -52.45% |
| Sep 30, 2021 | 250.93% |
| Jun 30, 2021 | -104.85% |
| Mar 31, 2021 | 63.60% |
| Dec 31, 2020 | -156.87% |
| Sep 30, 2020 | 59,872.73% |